Abstracts - PAGE Meeting (Population Approach Group Europe)

← Back to filters

Abstracts (68)

IV-01Khaled Abduljalil

Application of Physiologically-Based Pharmacokinetic model To Predict Tramadol Concentration in human Milk

Thursday 14:45-16:15

IV-02João Abrantes

Handling inter-occasion variability in model-based therapeutic drug monitoring

Thursday 14:45-16:15

IV-03Malidi Ahamadi

Operating Characteristics of Stepwise Covariate Selection in Pharmacometric Modeling

Thursday 14:45-16:15

IV-04Pascal André

Population pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute.

Thursday 14:45-16:15

IV-05Louise Andrews

New population pharmacokinetic model that predicts the individual starting dose of tacrolimus following pediatric renal transplantation

Thursday 14:45-16:15

IV-06Usman Arshad

Population pharmacokinetic model of mitotane enzyme autoinduction in adrenocortical carcinoma patients

Thursday 14:45-16:15

IV-07Muhammad Waqar Ashraf

A semi-mechanistic model to characterize the pharmacokinetics of orally administered S-Ketamine in healthy human subjects

Thursday 14:45-16:15

IV-08Eduardo Asín-Prieto

An Immune quantitative network aimed for viral hepatitis B

Thursday 14:45-16:15

IV-09Geraldine Celliere

Target-mediated drug-disposition (TMDD) model comparison using the MonolixSuite

Thursday 14:45-16:15

IV-10Hyun-moon Back

Development of a Semi-mechanistic absorption model for explaining effect of food on itraconazole

Thursday 14:45-16:15

IV-11Suruchi Bakshi

Systems pharmacology modelling of alternative pathway of complement activation

Thursday 14:45-16:15

IV-12Pavel Balazki

Physiologically-based Pharmacokinetics/Pharmacodynamics model of Dapagliflozin, an oral SGLT2 inhibitor

Thursday 14:45-16:15

IV-13Violeta Balbas-Martinez

Validation of a Network Systems Pharmacology model for Inflammatory Bowel

Thursday 14:45-16:15

IV-14Guillaume Baneyx

Population pharmacokinetic modeling of pazopanib in healthy volunteers and patients with advanced renal cell carcinoma.

Thursday 14:45-16:15

IV-15

Modelling body mass index trajectory in HIV-infected individuals

Thursday 14:45-16:15

IV-16Carla Bastida Fernández

Population pharmacokinetic model for intravenous tocilizumab in rheumatoid arthritis

Thursday 14:45-16:15

IV-17Brendan Bender

A Mechanism-Based Model of Tumor Quiescence and Resistance in HER2-Negative Metastatic Breast Cancer in Patients Receiving Docetaxel or Paclitaxel

Thursday 14:45-16:15

IV-18Sophie Berends

A Target-Mediated Drug Disposition model for infliximab in patients with Ulcerative Colitis

Thursday 14:45-16:15

IV-19Aliénor Bergès

Dose-exposure-response model between an ATR inhibitor and peripheral monocytes

Thursday 14:45-16:15

IV-20Julie Bertrand

Joint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients

Thursday 14:45-16:15

IV-21Souvik Bhattacharya

Longitudinal Parkinson’s Disease Progression Model using Item-Response-Theory Utilized to Predict Treatment Effect of Levodopa

Thursday 14:45-16:15

IV-22Bruno Bieth

Use of population PK/PD modeling to support the regulatory approval of canakinumab as first biologic treatment in patients with periodic fever syndromes

Thursday 14:45-16:15

IV-23Roberto Bizzotto

A model of insulin kinetics describing tests with various insulin secretion and infusion patterns by means of a consistent mechanism

Thursday 14:45-16:15

IV-24Agnieszka Borsuk-De Moor

Tigecycline population pharmacokinetics in patients with severe sepsis or septic shock resulting from abdominal surgery

Thursday 14:45-16:15

IV-25Thomas Bouillon

Efficient identification of the optimal dosing regimen with a nonparametric method

Thursday 14:45-16:15

IV-26

Parameter Estimation in Bivariate Mixed Hidden Markov Models

Thursday 14:45-16:15

IV-27Jantine Brussee

Distinguishing between first-pass and systemic CYP3A-mediated metabolism of midazolam in preterm neonates using physiologically-based pharmacokinetic modelling

Thursday 14:45-16:15

IV-28Núria Buil Bruna

Predicting myelosuppression from phase I data: Which model should we use?

Thursday 14:45-16:15

IV-29Charles Burdet

Joint modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers

Thursday 14:45-16:15

IV-30Unai Caballero

Pharmacokinetic/pharmacodynamic modeling of anidulafungin time-kill curves against Candida considering antifungal resistance

Thursday 14:45-16:15

IV-31Sophie Callies

Increase in glucose as pharmacodynamic biomarker following administration of the PI3K/mTOR inhibitor LY3023414: quantitative description using modelling.

Thursday 14:45-16:15

IV-32Elisa Calvier

Accuracy of plasma clearance scaling from adults to children using pathway-specific covariate models: a systematic investigation using a physiologically-based pharmacokinetic workflow

Thursday 14:45-16:15

IV-33Letizia Carrara

Which data are necessary to build a WB-PBPK model that accurately predicts exposure in the lung? A case study using Ethambutol for tuberculosis treatment

Thursday 14:45-16:15

IV-34Massimo Cella

CHF5993 a triple combination therapy for COPD patients: population PK modelling of glycopyrronium bromide (GB) following pMDI inhalation.

Thursday 14:45-16:15

IV-35Marc Cerou

Development and performance of npde for the evaluation of time-to-event model

Thursday 14:45-16:15

IV-36Anne Chain

An Extrapolation Approach to Aprepitant Pediatric Drug Development

Thursday 14:45-16:15

IV-37Kaelig Chatel

Tobramycin dose individualization using the MonolixSuite

Thursday 14:45-16:15

IV-38Jonathan Chauvin

Longitudinal Model-Based Meta-Analysis (MBMA) for rheumatoid arthritis with Monolix

Thursday 14:45-16:15

IV-39Chao Chen

A clinical trial simulation study to investigate and compare efficacy and toxicity findings in parallel and titration designs

Thursday 14:45-16:15

IV-40Dina Chernikova

Inhibition of bile acids synthesis via fibroblast growth factor 19 (FGF19) through intestinal signaling: A population analysis

Thursday 14:45-16:15

IV-41Manoranjenni Chetty

Prediction of the pharmacokinetics of renally excreted antiretrovirals in older patients, using physiologically based pharmacokinetic (PBPK) modelling.

Thursday 14:45-16:15

IV-42S. Y. Amy Cheung

Optimising Phase 1 oncology dosing schedule of an ATR inhibitor in real time using a model informed approach to predict myelosuppression

Thursday 14:45-16:15

IV-43Maxwell Chirehwa

A semi-physiological model for moxifloxacin pharmacokinetics which includes the effect of co-administered drugs and genetic polymorphisms

Thursday 14:45-16:15

IV-44Joannellyn Chiu

Pre-clinical Population PK Model of CF-301 – a Novel Antibacterial Lysin

Thursday 14:45-16:15

IV-45Palang Chotsiri

Population pharmacokinetic and time-to-event modelling of the antimalarial drug lumefantrine in young children with severe acute malnutrition

Thursday 14:45-16:15

IV-46Shafi Chowdhury

Using “Big” NONMEM Dataset Generated from Standard SDTM to Review Data and Accelerate Model Building Process

Thursday 14:45-16:15

IV-47Pieter Colin

Dexmedetomidine pharmacodynamics in healthy volunteers: Striking a balance between the hypnotic and sedative properties and the haemodynamic side effects.

Thursday 14:45-16:15

IV-48Camille Couffignal

Population pharmacokinetic modelling of sustained-release lithium in the serum, erythrocytes and urine of patients with bipolar disorder.

Thursday 14:45-16:15

IV-49Sinziana Cristea

The impact of renal transporters on paediatric renal clearance

Thursday 14:45-16:15

IV-50Vincent Croixmarie

DDMoRe private repository linked with an in-house PK database

Thursday 14:45-16:15

IV-51André Dallmann

Physiologically-based pharmacokinetic modeling of drugs metabolized via several CYP enzymes in populations of pregnant women

Thursday 14:45-16:15

IV-52Olivier David

CNP520 Phase III dose selection support: Identifying the doses producing a desired reduction in CSF Aß-40

Thursday 14:45-16:15

IV-53Miné De Kock

Population Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria.

Thursday 14:45-16:15

IV-54Mailys De Sousa Mendes

Predicting human foetal exposure using physiologically based pharmacokinetic models

Thursday 14:45-16:15

IV-55Aurelia de Vries Schultink

Modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens.

Thursday 14:45-16:15

IV-56

Modeling of telmisartan disposition in sandwich-cultured rat hepatocytes. Does cryopreservation change disposition kinetics?

Thursday 14:45-16:15

IV-57Douglas J. Eleveld

How many bits of information did my study provide? Examining Kullback-Leibler divergence, standard errors and shrinkage

Thursday 14:45-16:15

IV-58Chenhui Deng

Tofacitinib exposure-response modeling of partial Mayo score in ulcerative colitis patients in phase 3 induction studies

Thursday 14:45-16:15

IV-59Menshykau Denis

Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients

Thursday 14:45-16:15

IV-60Paolo Denti

Lopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials

Thursday 14:45-16:15

IV-61Solène Desmée

Mechanistic joint modelling for longitudinal PSA and survival data in advanced metastatic prostate cancer

Thursday 14:45-16:15

IV-62Cheikh Diack

A model-based meta-marker to characterize the response to ranibizumab in wet AMD patients

Thursday 14:45-16:15

IV-63

Towards population physiology based pharmacokinetics modelling (popPBPK) in an industrial environment

Thursday 14:45-16:15

IV-64Richard Dimelow

Effect of dataset characteristics on estimation method performance: a TMDD model example

Thursday 14:45-16:15

IV-65Christiane Dings

Mathematical modeling of glucose, insulin and c-peptide during the OGTT in pre-diabetic subjects: A DIRECT study

Thursday 14:45-16:15

IV-66Mike Dunlavey

Use of distributed delay in PML

Thursday 14:45-16:15

IV-67Sulav Duwal

Multiscale, mechanistic pipeline to assess the prophylactic efficacy of anti- HIV compounds

Thursday 14:45-16:15

IV-68Lisa Ehmann

Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients?

Thursday 14:45-16:15